scholarly journals PTEN/Akt Signaling through Epidermal Growth Factor Receptor Is Prerequisite for Angiogenesis by Hepatocellular Carcinoma Cells That Is Susceptible to Inhibition by Gefitinib

2006 ◽  
Vol 66 (10) ◽  
pp. 5346-5353 ◽  
Author(s):  
Shu-ichi Ueda ◽  
Yuji Basaki ◽  
Masumi Yoshie ◽  
Katsuhiro Ogawa ◽  
Shotaro Sakisaka ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Akt Signaling ◽  
Carcinoma Cells ◽  
Hepatocellular Carcinoma Cells ◽  
Epidermal Growth

Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells

2012 ◽  
Vol 57 (1) ◽  
pp. 108-115 ◽  
Author(s):  
Marie-José Blivet-Van Eggelpoël ◽  
Hamza Chettouh ◽  
Laetitia Fartoux ◽  
Lynda Aoudjehane ◽  
Véronique Barbu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Cell Response ◽  
Growth Factor Receptor ◽  
Carcinoma Cells ◽  
Hepatocellular Carcinoma Cells ◽  
Epidermal Growth

Interrupted crosstalk between natural killer cells and anti-epidermal growth factor receptor: a possible role in hepatocellular carcinoma treatment failure

2021 ◽  
Vol 21 ◽  
Author(s):  
Hadeer Abosalema ◽  
Shahenda Mahgoub ◽  
Mohamed Emara ◽  
Nahla Kotb ◽  
Sameh Soror
Keyword(s):  
Hepatocellular Carcinoma ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Major Health Problem ◽  
Advanced Stages ◽  
Epidermal Growth ◽  
First Time ◽  
Late Stages

: Hepatocellular carcinoma (HCC) is a major health problem worldwide. Most patients are diagnosed for the first time at late stages; this leads to a very poor prognosis. It is challenging to discover strategies for treatment at these advanced stages. Recently, monoclonal antibodies (mAbs) targeting specific cellular signaling pathways in HCC have been developed. Unfortunately, they still have a low survival rate, and some of them failed clinically to produce effective responses even if they showed very good results against HCC in preclinical studies. This review focuses on and discusses the possible causes for the failure of mAbs, precisely anti-Epidermal Growth Factor Receptor (EGFR) mAb and the crosstalk between this mAb and patients' NK cells.

Sign in / Sign up

Export Citation Format

Share Document